Research progress of SLC1A2 gene and essential tremor / 中国医师杂志

Essential tremor (ET) is a common dyskinesia disease characterized by tremor. ET is clinically heterogeneous. In addition to the motor symptoms with tremor as the main manifestation, it also includes non-motor symptoms such as neuropsychiatric symptoms (anxiety, depression), personality changes, sleep disorders, etc. Among them, anxiety and depression are the most common, and gradually worsen as the disease progresses, causing adverse effects on the quality of life of patients. Therefore, the early clinical full text of looking for ET psychiatric symptoms seems to have no content of the evaluation scale and is irrelevant. It is suggested that removing biomarkers plays an important role in the diagnosis and treatment of ET patients. Genome-Wide Association Studies (GWAS) describes the SLC1A2 gene associated with ET, and the EAAT2 or GLT1 encoded by this gene is associated with the anxiety and depression phenotypes of ET patients in non-motor symptoms. Up to now, the pathogenesis of ET patients is not clear, but many reports confirm that genetic factors play an important role in the pathogenesis of ET. Among them, SLC1A2 is expected to become a biomarker of the neuropsychiatric phenotype of the disease, providing a basis for clinical workers to take corresponding intervention measures in time. This article reviews SLC1A2 gene and essential tremor.

Research progress of olfactory dysfunction in Parkinson′s disease / 中国医师杂志

Parkinson′s disease (PD) is the second most common neurodegenerative disease in middle-aged and elderly people. In addition to motor symptoms, PD also has many non motor symptoms, such as dysosmia, constipation, cognitive impairment, etc. Among them, dysosmia is a common non motor symptom of early Parkinson′s disease. Research has confirmed that olfactory dysfunction (OD) can appear before the typical clinical symptoms of PD, which is of great significance to the diagnosis and treatment of diseases. However, at present, the pathogenesis of OD is still unclear, and the inspection methods have not been unified, and there is no complete cure. This article reviews the latest research progress of dysosmia in Parkinson′s disease.

New progress of mitochondrial dysfunction in the pathogenesis of Parkinson′s disease / 中国医师杂志

Parkinson′s disease (PD) is a neurodegenerative disease commonly found in middle-aged and elderly people. It is characterized by resting tremor, bradykinesia, myotonia, and abnormal posture gait. The main pathological changes were the loss of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies in the cytoplasm of the residual neurons. The main component of the Lewy bodies was α-synuclein. And why it causes the degeneration of dopaminergic neurons in the substantia nigra is not known. At present, most studies on Parkinson′s disease focus on the pathogenesis of the disease. More and more evidence shows that respiratory chain injury is a key feature of sporadic PD patients, and the proteins encoded by PD-related genes are related to the disorder of mitochondrial function. We believe that the important mechanism of the disease is impaired mitochondrial function due to environmental and (or) genetic inheritance. This article highlights new advances in mitochondrial dysfunction in Parkinson′s pathogenesis, including mitochondria and cell-mediated immunity, endoplasmic reticulum (ER)-mitochondrial axis, sirtuin-mediated mitochondrial stress response, and the role of microRNA in the etiology of PD. A deeper understanding of these mechanisms may provide inspiration for the development of new targeted therapies.

Research progress on non motor symptoms of Parkinson's disease / 中国医师杂志

Parkinson's disease (PD) is a type of degenerative disease of the nervous system.In addition to its typical clinical symptoms,non-motor symptoms mainly include sensory disorders,neuropsychiatric disorders and autonomic nerve disorders,which also have serious effects on patients.This article reviews the performance,mechanism of non-motor symptoms to improve clinicians' attention and improve the quality of life for Parkinson's patients.

The research progress of mild cognitive impairment in Parkinson's disease / 中国医师杂志

Parkinson's disease (PD) is a neurodegenerative disease characterized by degeneration and deletion of dopaminergic neurons in the substantia nigra and a pathological feature of the Louis body.The clinical manifestations including non motor symptoms and motor symptoms.Cognitive impairment (CI)is one of the most common non motor symptoms in patients with PD,Which includes mild cognitive impairment (MCI) and dementia.MCI is an early manifestation of dementia in PD.Therefore,early diagnosis and treatment of MCI are very important for the prognosis of PD.The epidemiology,risk factors,heredity,biomarkers,imaging,diagnosis and treatment of MCI in PD are reviewed in this paper.

Research progress of Parkinson's frozen gait / 中国医师杂志

Parkinson's disease is a neurodegenerative disease characterized by static tremor, myoto-nia, motor retardation and abnormal posture and gait. Freezing of gait ( FOG) is a common symptom of ad-vanced Parkinson's disease. At present, the pathogenesis of frozen of gait is not clear, and treatment is still difficult. This article reviews the latest progress and treatment of frozen gait in Parkinson's disease patients and makes a prospect.

Influence of δ-opioid receptor in the central nervous system / 中国医师杂志

The delta-opioid receptor (DOR),which is a classic analgesic drug widely existed in the central system and peripheral system,is a kind of inhibitory G-protein coupled receptor with seven transmembrane regions.In addition to pain modulation,the opioid receptors are involved in various physiological and pathological activities through gene or cytokines.This review addresses the influence and possible mechanisms of the delta-opioid receptor in ischemic brain injury,analgesia,anti-anxiety and depression,learning and memory,and Parkinson's disease.

A meta-analysis on clinical effect of acupuncture for Parkinson disease / 中国医师杂志

Objective To evaluate the clinical effect of acupuncture on Parkison disease (PD) with systematic review in view of evidence-based medicine (EBM).Methods Articles on clinical effect of acupuncture on Parkinson disease published from the database-established year to May of 2017 we searched from China National Knowledge Internet (CNKI),Wanfang,VIP,Chinese Biomedical Literature Database (CBM),PubMed,and Cochrane Library databases without language limitation.Quality evaluation and data extraction were carried out according to the tool for assessing risk of bias provided by the Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1.0).All statistical analyses were performed with Reviewer Manager Software (Version 5.3;Cochrane Collaboration,Oxford,UK).Assessments were performed with the total effective rate,the scores of each scale (the unified Parkinson disease rating scales-UPDRS and the Webster scale),and the improvement of different clinical manifestation.Results In all,12 randomized controlled trials (RCTs) met our inclusion criterion,a total of 892 patients,including 468 cases in the experimental group (acupunctuer with or without medicine) and 424 cases in the control group (medicine only).Meta-analysis showed favorable results for the experimental group compared to control group in the total effective rate,the total scales of UPDRS and the modified Webster scale [OR =2.16,95％ CI (1.57,2.97),P＜0.01;OR =7.20,95％ CI(4.02,10.37),P＜0.01;OR=3.33,95％ CI(2.13,4.53),P ＜0.01].The experimental group was effective in relieving partial symptoms of PD such as rigidity,postural,gait,bradykinesia compared to the control group,while there was no significant difference in tremor at rest and sit-stand up movements (P ＞ 0.05).Conclusions Acupuncture had certain clinical effect on Parkinson disease,it can relieve the clinical symptoms of Parkinson disease to some extent,and postpone the progression of PD,which improves the quality of life of PD patients.Acupuncture can be recommended as a combination treatment for Parkinson disease.